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This randomized double-blind, placebo-controlled study investigated the safety and efficacy of Labisia 
pumila (LP) water extract on sexual health, lipid profile and inflammatory markers in 36 healthy pre-and 
post-menopausal North American women. Participants were randomized to either LP (200 mg) or 
placebo for 12 weeks. The female sexual function index (FSFI) and short form-36 health survey (SF-36) 
were completed, and lipid profiles, anti-inflammatory markers, urinary antioxidants and safety 
parameters were assessed. There were no significant differences in FSFI and SF-36 scores after 12 
weeks. Compared to placebo, women on Labisia pumila trended towards a reduction in total cholesterol 
after 12 weeks (p=0.077). Urinary 8-isoprostane concentrations from baseline to week 12 decreased for 
both groups, with women on L. pumila demonstrating a greater decrease (Δ= -144.4nmol/L) versus 
placebo (Δ= -125.9nmol/L). Significant decreases in serum IL-6 from baseline to week 6 were observed 
in Labisia pumila and placebo (p=0.006 and p=0.012 respectively) but these differences were not 
sustained through week 12. LP demonstrated a trend towards an improvement in TC, urinary 8-
isoprostane and significant within group improvement in IL-6 and IL-1β suggesting a role for LP in 
improving inflammation. Future research should focus on older subjects that are sexually 
dysfunctional.  
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A high proportion of North American women experience 
low sexual desire, difficulties with orgasm and painful and 
un-pleasurable intercourse (Pujols et al., 2010). The 
National Health and Social Life Survey, a well-designed, 
large population-based study on adults ranging from ages 
18 to 59, found a high overall prevalence of female 
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sexual dysfunction in US women (Goldstein et al., 2004). 
Sexual dissatisfaction was associated with sexual 
dysfunction, and women who reported greater distress 
over sexual problems also reported greater sexual 
dissatisfaction (King et al., 2007).  
Though satisfaction with sexual function in women has 
not been well-described, and little is known of the 
differences in sexual function between pre- and post-
menopausal women (Davison et al., 2008), sexual activity 
has been shown to decline with age (Dennerstein et al., 
2005). In studies with methodology that allows the effects 
of menopausal status to be separated from aging, it is 
clear that there is a further effect on sexual function of 
menopausal status over that of aging (Dennerstein et al., 
2005). Estrogen secretion declines to very low levels 
post-menopause; this results in vulvovaginal atrophy and 
can lead to sexual pain and trauma during intercourse 
(Buster, 2013). Neuroendocrinal effects of declining 
estrogen levels, including mood swings, hot flushes, 
irritability, memory lapses and insomnia also adversely 
affect sexual response (Buster, 2013). As well, there are 
some evidence to suggest a link between sexual 
dysfunction and cardiovascular disease (Archer et al., 
2005; Steinke, 2010). 
Labisia pumila var alata (family Myrsinaceae), is a well-
known and popular herb for feminine vitality, sexual 
wellbeing and hormonal balance in South East Asia 
(Burkill et al., 1966; Gimlett, 1971; Lemmens et al., 
2002). Previous in vitro and in vivo studies report that 
extracts of L. pumila (LP) have various immunomo-
dulatory (Pandey et al., 2008), antioxidant (Tasduq et al., 
2007), lypolytic (Al-Wahabi et al., 2007) and aphrodisiac 
effects (Asiah et al., 2007). Several bioactive constituents 
have been identified in the extract including benzo-
quinones (Houghton et al., 1999), alkenyl resorcinols 
(Jamal and Houghton, 1999) and triterpenoids (Jamal, 
2006), as well as flavonoids (apigenin, kaempferol, rutin 
and myricetin), isoflavonoids and phenolic compounds 
(gallic acid, pyrogallol and caffeic acid) (Chua et al., 
2011; Karimi and Jaafar, 2011; Karimi et al., 2011; Chua 
et al., 2012). Water extracts of LP have long been used 
for gynecological issues in traditional medicine (Ismail et 
al., 1999), but there is limited clinical evidence on safety 
and efficacy. Traditionally, this herb is taken for pre-
menstrual problems, post-labor tonic and a general tonic 
for women’s health presenting uses in women of varying 
ages (Burkill et al., 1966; Gimlett, 1971; Ismail et al., 
1999). Malay women use LP for muscle pain, uterine 
health and sexual satisfaction (Intan et al., 2005). A 
previous study on postmenopausal women showed that 
LP extract was safe (Nik Hazlina et al., 2009a, b).  
The aim of this 12-week pilot study was to provide 
further evidence on the efficacy of LP on sexual well-
being, quality of life and cardiovascular health and safety 
in North American women. A wide age group, from 18 to 
70 years of age, was considered for this study to deter-
mine the group likely to benefit from LP supplementation.  




MATERIALS AND METHODS 
 
Ethical approval of the study 
 
This study was conducted in accordance with the Guideline for 
Good Clinical Practice (ICH-6) and Declaration of Helsinki. 
Authorization was received from the Natural Health Products 
Directorate on December 09, 2009 and unconditional approval was 
granted by Institutional Review Board Services, Aurora, Ontario, 
Canada on January 08, 2010. The study was conducted at a single 
site; KGK Synergize Inc., London, Ontario, Canada. 
 
 
Study population, sampling and recruitment 
 
The pilot study was a single-site, randomized, double-blind, placebo 
controlled 12-week parallel study in 36 healthy women. Women 
were recruited from a research subject database and adver-
tisements in newspapers.  
Women were included in the study if they were between 18 and 
70 years of age, regardless of level of sexual activity, were healthy 
as determined by laboratory results, medical history and physical 
examination and gave informed written consent. Women were 
excluded if they reported sexual dysfunction, were on hormone 
therapy, allergic to study products, pregnant or breast feeding, or 
had a history of breast, uterine or ovarian cancer, autoimmune 
conditions, immunodeficiency, history of bleeding disorders, 
gynecological disease, any serious gastrointestinal, hepatic, renal, 
cardiovascular, neurological or hematological disorder; drug or 
alcohol abuse or on natural health products/dietary supplements 
within two weeks prior to randomization. 
 
 
Randomization and intervention 
 
Subjects were randomly assigned to two treatment groups in a 1:1 
ratio using computer-generated randomization tables into 18 blocks 
of two to receive either one tablet of LP water extract or a matching 
placebo, once daily for 12 weeks. Randomization was stratified 
based on menopausal status; pre-menopausal or post-menopausal 
(>1 year since last menstruation).  
Pre-menopausal women were randomized starting from the top 
of the randomization schedule and postmenopausal women were 
randomized starting from the bottom of the randomization schedule 




Experimental design and investigational product 
 
After enrollment at baseline (day 0), follow-up visits occurred at six 
weeks (day 42 ± 3) and 12 weeks (day 84 ± 3). During the 
intervention, each participant consumed 1 tablet containing either 
LP or placebo in the morning after breakfast. The study product LP 
consisted of 200 mg of aqueous extract of LP root and leaves (BIO 
LP101) with polygonum minus, calcium phosphate monobasic, 
microcrystalline cellulose, hydroxymethyl cellulose, cellulose, silicon 
dioxide, magnesium stearate, talcum, hypromellose, sodium 
carboxymethyl cellulose, iron oxide red, titanium dioxide, beet root 
powder, macrogol 6000, maltodextrin as excipients, and was 
manufactured under continuous quality control of Good 
Manufacturing Process requirements (batch number: 30 PED 060; 
DER: 10:1; Biotropics Malaysia Berhad, Kuala Lumpur, Malaysia). 
The placebo tablet corresponded to the active medication without 
the herbal extract. The dosage used in this study was based on 
both a combination of scientific data from animal studies, using 1/7 
species conversion  factor, and  traditional use studies (Freireich et  
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al., 1966; Samy et. al., 2005; Kadir et al., 2012). 
 
 
Primary outcome measure 
 
The primary endpoints were determined by measuring the 
improvement in quality of life at each visit, using the female sexual 
function index (FSFI) and RAND Short Form-36 Health Survey (SF-
36) questionnaires. The FSFI questionnaire included 19 questions 
which overlapped six domains: desire, arousal, lubrication, orgasm, 
satisfaction and pain (Rosen et al., 2000). The SF-36 scale 
included questions classified in the following domains: Total 
physical, total mental, physical functioning, role physical, bodily 




Secondary outcome measure 
 
The secondary outcomes included plasma lipid profile (total 
cholesterol (TC), high density lipoprotein-C (HDL-C), low density 
lipoprotein-C (LDL-C), triglycerides), antioxidants (8-isoprostane, 
serum superoxide dismutase (SOD), anti-inflammatory markers 
(cytokines TNFα, interleukin (IL)-6, IL-1β), hormones (estradiol-
17β), blood chemistry (electrolytes, glucose, creatinine and 
bilirubin), liver function markers (aspartate aminotransferase (AST), 
alanine transaminase (ALT), gamma-glutamyl transferase (GGT)), 
hematology (complete blood count- (CBC), weight and vital signs. 
The secondary objectives were assessed at baseline and at 6 and 
12 weeks of treatment. Two, first-morning void urine samples were 
collected the day before and the day of the study visit, and were 
pooled and analyzed for creatinine and 8-isoprostane. Adverse 
events (AEs) were documented at each visit and were classified 
according to the description, duration, severity, frequency and 
outcome. Their relationship to the investigational product was 





Blood was collected into 4 ml ethylenediaminetetraacetic acid 
(EDTA) tubes. Serum generated was analyzed to determine 
hematology, plasma lipid profiles, blood chemistry and liver function 
endpoints (LifeLabs Medical Laboratory Services, London, ON, 
Canada). Serum was frozen and stored at -40°C for the 
measurement of cytokines and SOD by enzyme linked immuno-
sorbent assay (ELISA): TNFα (catalog no. 555212, BD Bioscience, 
Mississauga, ON, Canada), IL-6 (catalog no. 555220, BD 
Bioscience, Mississauga, ON, Canada), and IL-1β (catalog number 
557953, BD Bioscience, Mississauga, ON, Canada) SOD (catalog 
no. 706002, Caymen Chemical, Ann Arbor, MI, USA). Aliquots of 1 
ml of urine were frozen at -40°C for urinary 8-isoprostane analysis 






No formal sample size calculation was conducted for this study due 
to the lack of efficacy data for LP treatment for quality of life 
parameters. The planned sample size for this study was 36 
participants with 18 women randomized equally to each of the two 
study arms. Allowing for an anticipated drop-out-rate of 15%, 30 
women were expected to complete the trial. Drop-outs during the 
treatment period or participants leaving the study prematurely were 
not replaced.  
All subjects were included for analysis of safety and efficacy. 
Between-group comparisons were made using analysis of cova-





group changes were made using t-tests. Fisher’s exact test was 
used for comparing frequencies between groups for categorical 
data. Compliance, defined as the number of pills taken, in the two 
groups was analysed using t-test. Probability values ≤0.05 were 
considered statistically significant.  
A subgroup analysis on sexually active women stratified by age 
(18-29 years, 30-39 years, 40-49 years and ≥50 years) was 
conducted. During statistical analysis, subjects were classified 
based on FSFI scores and those with scores ≤26 were considered 
sexually dysfunctional (Wiegel et al., 2005). An interaction test was 
conducted to test whether or not the difference between the two 
groups in one age category was different from that seen in another 
age category (Pocock and Enderlein, 1985). SAS Version 9.1 was 







Subject disposition is shown in Figure 1. Baseline 
demographic and blood chemistry measures were 
comparable between the two groups at screening, but 
participants receiving LP had significantly lower body 
weight (p=0.019) and body mass index (BMI) (p=0.04) 
(Table 1).  
At screening, subjects on LP also had lower mean 
fasting glucose levels (p=0.026) than those receiving 
placebo though the values remained well within normal 
clinical range, and there was no significant difference in 
fasting glucose levels between groups at baseline, week 
6 and week 12. Three subjects in the LP group and four 
in the placebo group were post-menopausal. Fewer 
participants in the LP group consumed alcohol on a 
weekly basis versus placebo, which trended towards 
significance. Mean compliance was 93% in LP group and 
91% in placebo group. 
 
 
Female sexual function index (FSFI) 
 
There were no significant differences between groups in 
the total FSFI score (Table 2) or domain scores for 
desire, arousal, lubrication, orgasm, satisfaction and pain 
at baseline or at 6 and 12 weeks of treatment. Within 
groups, after six weeks of supplementation, subjects on 
placebo reported significantly higher lubrication 
(p=0.022), orgasm (p=0.048) and total FSFI scores 
(p=0.05).  
These subjects also showed trends in arousal 
(p=0.067) and pain (p=0.10) scores at week 6. However 
significance and trends were not maintained through 
week 12. At week 12, a greater increase in the mean total 
FSFI score from baseline was reported by women on LP 
versus placebo (0.8 versus 0.4) (Figure 2). 
 
 
Short form (36) health survey  
 
There were no statistically significant differences between










Table 1. Demographics and characteristics all subjects randomized into the study. 
 
Parameter 
Labisia pumila (N=18) Placebo (N=18) 
p-value 
Mean ± SD Mean ± SD 
Age (years) 39.1 ± 13.0 40.4 ± 12.5 0.756
1
 





) 22.8 ± 3.4 25.5 ± 4.3 0.041
1
 
Alcohol Use [f/n (%)]    
None 6/18 (33.3%) 1/18 (5.6%) 
0.059
2 
Occasional 9/18 (50.0%) 9/18 (50.0%) 
Weekly 3/18 (16.7%) 8/18 (44.4%) 
Tobacco Use [f/n (%)]    
Current 2/18 (11.1%) 0/18 (0.0%) 
0.241
2
 Former 2/18 (11.1%) 5/18 (27.8%) 
Never 14/18 (77.8%) 13/18 (72.2%) 
 
1
Between group comparisons were made using analysis of variance (ANOVA). 
Probability values P<0.05 are statistically significant; 
2
between group comparisons were 




treatment and placebo groups with respect to the total 
SF-36 score or the domains (total physical, total mental, 
physical functioning, role physical, bodily pain, general 
health, vitality, social functioning, role emotion and 
mental health) at baseline or after 6 and 12 weeks of 















N=0 Withdrawn  
N=2 Withdrawn  
Reasons: 
Subject request (N=1) 
Lost to follow up (N=1) 
 
Subject request (N=1) 
Lost to follow up (N=1) 
N=18  
Randomized to Labisia pumila 
N= 18  
Randomized to Placebo 
N=1 Withdrawn  
Reasons: 
Non compliance (N=1) 
 
 
N=1 Withdrawn  
Reasons:  






Did not meet eligibility criteria 
Exclusion Criteria (N=11) 
Withdrew Consent (N=2) 
 




Table 2. Total FSFI score of all subjects randomized into the study at 
baseline, 6 weeks and 12 weeks. 
 
Parameter 
Labisia pumila Placebo 
p-value 
[N] Mean ± SD [N] Mean ± SD 
FSFI Total (score range 2.0 - 36.0, higher is better) 
Week 0 (Baseline) [17] 24.6 ± 9.7 [15] 26.9 ± 7.7 0.473
1 
Week 6 [17] 25.9 ± 7.5 [17] 28.9 ± 6.1 0.320
2 




Between group comparisons were made using a t-test. Probability values 
P<0.05 are statistically significant; 
2
Between group comparisons were made 
using analysis of covariance (ANCOVA) using baseline as a covariate. 






Figure 2. The within-group change of total FSFI score from baseline to week 6 and week 




Table 3. Total SF-36 score of all subjects randomized into the study 
at baseline, 6 weeks and 12 weeks. 
 
Parameter 
Labisia pumila Placebo 
p-value 
[N] Mean ± SD [N] Mean ± SD 
SF 36 Total (Score Range 0.0 - 100.0, Higher is better) 
Week 0 (Baseline) [18] 89.5 ± 5.9 [18] 90.6 ± 4.9 0.520
1 
Week 6 [18] 88.2 ± 5.2 [18] 87.1 ± 9.8 0.442
2 




Between group comparisons were made using a t-test. Probability values 
P<0.05 are statistically significant; 
2
between group comparisons were 
made using analysis of covariance (ANCOVA) using baseline as a 






For women on LP, TC decreased from baseline to week 
12 and when compared to placebo, this trended towards 
a significant difference (Table 4). Compared to placebo, 











































Labisia pumila Placebo 
p-value 
[N] Mean ± SD [N] Mean ± SD 
Total cholesterol (mmol/L)    
Week 0 (Baseline) [18] 5.0 ± 1.0 [18] 4.9 ± 1.1 0.882
1 
Week 6 [18] 4.9 ± 1.1 [18] 4.9 ± 1.0 0.791
2 
Week 12 [16] 4.8 ± 1.0 [17] 5.2 ± 0.9 0.077
2 
LDL-C (mmol/L)    
Week 0 (Baseline) [18] 3.0 ± 0.9 [18] 2.8 ± 1.0 0.645
 1 
Week 6 [18] 2.9 ± 0.9 [18] 2.8 ± 0.9 0.648
 2 
Week 12 [16] 2.9 ± 0.8 [17] 3.0 ± 0.8 0.194
 2 
HDL-C (mmol/L)    
Week 0 (Baseline) [18] 1.5 ± 0.3 [18] 1.7 ± 0.3 0.270
 1 
Week 6 [18] 1.6 ± 0.3 [18] 1.7 ± 0.3 0.197
 2 
Week 12 [16] 1.5 ± 0.3 [17] 1.8 ± 0.3 0.011
 2 
Triglyceride (mmol/L)    
Week 0 (Baseline) [18] 0.9 ± 0.3 [18] 0.9 ± 0.3 0.538
 1 
Week 6 [18] 1.1 ± 0.6 [18] 0.9 ± 0.3 0.159
 2 
Week 12 [16] 1.0 ± 0.5 [17] 0.9 ± 0.4 0.441
 2 
Total cholesterol/HDL-C ratio    
Week 0 (Baseline) [18] 3.3 ± 0.8 [18] 3.0 ± 0.7 0.276
 1 
Week 6 [18] 3.2 ± 0.9 [18] 2.9 ± 0.6 0.326
 2 




Between group comparisons were made using a t-test. Probability values P<0.05 are 
statistically significant; 
2
between group comparisons were made using analysis of 





TCC after 12 weeks (p=0.077) (Table 4). HDL-C 
increased significantly after 12 weeks of treatment in 
women on placebo, whereas those taking LP maintained 
baseline levels. The TC/HDL-C ratio was not significantly 





Changes in serum estradiol-17β were not statistically 
significant between- or within-groups at baseline, week 6 
or week 12 for either treatment. Women aged ≥ 50 years 
showed the lowest estradiol levels during the study 
period indicating age-related physiological changes 
associated with menopausal status (< 130 pmol/L). This 
age category also demonstrated no change from baseline 
in hormone levels in either treatment group suggesting 
that LP did not adversely affect estradiol levels. 
 
 
Oxidative stress markers and cytokines 
 
There were no significant differences in the oxidative 
stress markers 8-isoprostane and SOD at baseline, week 
6 or week 12. However, both groups demonstrated a 
decreasing trend in urinary 8-isoprostane concentrations 
from baseline to week 12, with women on LP having a 
greater decrease (Δ= -144.4 nmol/L) versus placebo (Δ= 
-125.9 nmol/L). Compared to baseline, TNF-α decreased 
in subjects on placebo and increased in subjects on LP 
after 12 weeks of supplementation; however these 
changes were not significant. There were significant 
within-group decreases in serum IL-6 from baseline to 
week 6 in both LP (p=0.006) and placebo (p=0.012) but 
these differences were not sustained through week 12. 
IL-1β was significantly decreased in women on LP from 
baseline to week 6 and week 12 (p<0.001, p=0.001) 
(Figure 3). There were no significant differences between 






Subgroup analysis of sexually dysfunctional women was 
classified by baseline FSFI scores ≤26, but sexually 
active for the duration of the study, showed that women 
taking LP had significantly higher “orgasm” scores versus  






Figure 3. The change from baseline of serum (A) IL-6 and (B) IL-1β concentration 
at week 6 and 12 for subjects on Labisia pumila (white) or placebo (grey). Within-
group comparisons were made using a t-test and * represents within group 




those on placebo (4.1 vs. 2.8, p=0.037). In contrast, 
women on placebo demonstrated significantly higher 
scores for “arousal” after 6 weeks of treatment versus 
women on LP (p=0.046); however, these scores were not 
maintained to week 12. When sexually active women 
were analyzed to determine whether the difference 
between LP and placebo was different between age 
groups (18-29, 30-39, 40-49 and ≥50 years), no 
significant interaction was found for age and total FSFI 
score, or any individual domain score after 6 and 12 
weeks of treatment.  
Safety evaluation 
 
No serious AEs were reported during the study. The 
number of participants reporting AEs was similar in both 
groups (Table 5). In the placebo group, seven AEs with 
“possible relation to the treatment” were reported by four 
participants, while five AEs were reported by four 
participants in the LP group. All AEs except one resolved 
without any intervention. The other was menstrual 
cramping and resolved with concomitant medication. Vital 




















































































Table 5. Adverse events with “possible” causal relation to the study medication. 
 
Study group Number of subjects Adverse events “possibly” related to the medication listed for each subject 
Labisia pumila 4  Nausea, menstrual cramps, vaginal spotting, mood alteration, stomach gas 
   
Placebo 4 
Breast tenderness, increased vaginal wetness, increased flatulence 









Sexual desire is a complex phenomenon that involves 
physiological and psychological influences and is thus 
difficult to treat (Jha and Thakar, 2010). Therapy options 
vary depending on the cause of sexual dysfunction, 
including the use of psychotherapy, prescription of 
estrogens, progestins or testosterone (Buster, 2013), but 
the gaps in the body of information related to female 
sexual dysfunction result in the condition remaining 
under-reported and poorly managed (Jha and Thakar, 
2010). Extracts of LP have a history of use in South-East 
Asian women to maintain reproductive function and 
enhance sexual function (Melissa et al., 2012). To date, 
only one pilot human study has been published on the 
efficacy of water-soluble extracts of LP on menopausal 
symptoms, cardiovascular risk factors and hormonal 
profiles of Malay postmenopausal women (Kadir et al., 
2012). The current study is the first to investigate the 
safety and efficacy of LP in a North American population 
of pre- and postmenopausal women.  
This study recruited healthy women regardless of their 
level of sexual activity, as FSFI scores were not used as 
criteria for enrollment. Based on an FSFI cut off score of 
≤26, only seven out of 36 enrolled participants were 
classified as sexually dysfunctional, and two were not 
sexually active for the duration of the study. As the 
majority of subjects in this trial were already sexually 
functional females, highlighting the effectiveness of LP in 
improving FSFI scores may have been confounded. 
Statistically significant results may have been more easily 
obtained if recruitment was limited to sexually active but 
sexually dysfunctional women (FSFI ≤ 26). Further, the 
absence of differences in FSFI scores between LP and 
placebo may be due to the wide age range of subjects. 
Subgroup analysis of FSFI scores on sexually active 
females showed that participants aged 30-39 years, 40-
49 years and ≥50 years on herbal treatment performed 
better than females who were 18-29 years, though no 
definitive conclusions can be reached due to the small 
sample size.  
Analysis of participants identified as sexually 
dysfunctional at baseline (FSFI ≤ 26) showed that women 
on LP reported significantly improved scores at week 6 in 
the “orgasm” domain versus those on the placebo; while 
higher scores continued to be reported at week 12 in 
women on LP, these did not reach significance. These 
results are consistent with literature as LP is reported to 
have aphrodisiac properties (Asiah et al., 2007). A 
bioactive peptide, recognized as an aphrodisiac marker, 
has also been identified in L. pumila (Asiah et al., 2007), 
perhaps eliciting improvements in FSFI scores. The total 
FSFI scores were improved in women identified with 
sexual dysfunction in both LP and placebo groups, 
though no definitive conclusions can be reached due to 
the small sample size.  
The results of the self-reported SF-36 were not 
influenced by LP or placebo. Results from a previous 
study, in middle aged women, showed that while serious 
illness, employment and marital status were significant 
predictors of quality of life, hormone replacement therapy 
use and menopausal status were not (O’Dea et al., 
1999). In a recent placebo-controlled double-blind study 
in Malaysian women between the ages of 40 and 60 
years, a water extract of LP reduced anxiety levels by 
55% compared to placebo (unpublished data). In the 
current study, the high baseline SF-36 and FSFI scores 
may have limited the response to the quality of life 
measures.  
Water extracts of LP inhibit estradiol binding to 
antibodies against estradiol suggesting the presence of 
estrogen-like or estrogenic compounds (Husniza, 2000). 
Water extracts of LP were found to exhibit high 
estrogenic activity when tested in an in vitro alkaline 
phosphatase assay using Ishikawa cells and low 
induction of cell proliferation when compared against a 
positive estradiol control (Melissa et al., 2013). A study 
on Wistar rats found that treatment with either LP or 
estrogen replacement therapy had similar efficacy in 
preventing estrogen deficiency-induced changes from 
ovariectomy by regulating RANKL, OPG and BMP-2 
gene expressions in femoral bones (Fathilah et al., 2013). 
In the current study, 44% females on placebo 
consumed alcohol weekly in comparison to 17% on LP. 
Furthermore, 11% of females on LP were current 
smokers while none were smokers in the placebo group. 
As alcohol consumption increases circulating estrogen 
and androgen levels
 
(Purohit, 1998), and smoking has 
anti-estrogenic effects (Tanko and Christiansen, 2004), 
these demographic differences may have impacted the 
results of the current study. Furthermore, participants on 
placebo had a significantly higher BMI and body weight at 
baseline in comparison  to  participants  on LP. Increased 




BMI, waist circumference and hip circumference are 
associated with increased levels of estrone, estradiol and 
free estradiol (Purohit, 1998), which may have influenced 
the results of the current study. Conclusions regarding 
the interaction between age and estradiol levels are 
difficult, since these parameters are dependent on the 
stage of the menstrual cycle at the time of blood sampling 
as well as the presence or absence of menstruation in 
the age groups. LP may be efficacious in older females 
deficient in female hormones; however, this was not 
specifically examined in this study. Previous data did not 
show significant fluctuations in follicle-stimulating 
hormone, luteinizing hormone and estradiol during a 280 
mg/day intake of LP sprayed-dried water extract in 29 
postmenopausal women versus placebo (Nik Hazlina et 
al., 2009b).  
The link between cardiovascular disease (CVD) and 
sexual dysfunction in males is well-established; mild or 
moderate erectile dysfunction is much more common in 
patients with CVD (Archer et al., 2005). In contrast, 
sexual dysfunction in women with CVD has received 
limited attention (Steinke, 2010). Research has shown 
that the mechanism of clitoral engorgement is very similar 
to penile erection, and thus may also be adversely 
affected by CVD (Steinke, 2010). Neuropathy or vascular 
disease resulting from CVD risk factors such as 
hypertension, smoking, diabetes or hyperlipidemia are 
known organic causes to female sexual dysfunction 
(Archer et al., 2005).  
Studies on rats showed a dose dependent decrease in 
TC with increasing doses of LP extract (unpublished). A 
significant reduction in trigly-cerides was also reported in 
post menopausal women on sprayed-dried water extract 
of LP for six months (Nik Hazlina et al., 2009a). 8-
isoprostane is regarded as one of the best indices of lipid 
peroxidation and oxidative stress (Tanko and 
Christiansen, 2004). The decreasing trend in TC and 
urinary 8-isoprostane from baseline to week 12 seen in 
the current study, together with the literature, suggests a 
role for LP in decreasing CVD risk in women.  
The analysis of renal and liver function tests, CBC and 
other clinical chemistry parameters showed that L. pumila 
was safe and well tolerated at a dose of 200 mg/day in 
the population studied. This is consistent with data from a 
six-month randomized placebo-controlled trial in postmen-
pausal women using dose regimens of up to 560 mg 
sprayed-dried water extract of LP (McTiernan et al., 
2006; Nik Hazlina et al., 2009a; Nik Hazlina et al., 
2009b).   
The randomization schedule was designed to prevent 
an imbalance between groups with respect to meno-
pausal status; therefore it is possible to suggest that the 
menopausal status of women did not affect the compa-
rability of data between groups. As this was a pilot study, 
the purpose being to explore the effects of LP over a 
wide range of women, recruitment of subjects were not 





An analysis of sexually active women on LP or placebo 
found no significant interaction between age and total 
FSFI scores, or any individual domain scores after 6 and 
12 weeks of treatment. However, this may certainly be 
due to the small sample sizes of the subgroups. The 
small sample size limited the ability to stratify the 
population by age, BMI and menstrual status, and was 
certainly a limitation of this study and may have impacted 
the results. Identifying populations by sexual dysfunction 
defined by FSFI at recruitment as well as those sexually 
active may have provided better evaluation of the efficacy 
of L. pumila in improving sexual function. Lastly, the 
improvements in FSFI scores in the placebo group at 
week 6 that were not sustained through to week 12 could 
have been expected, as previous reports have suggested 
a placebo response in the treatment of sexual 
dysfunction (Bradford and Meston, 2009, 2011). A run-in 
period prior to enrollment in the study may have improved 






This study investigates the efficacy of LP in healthy 
women regardless of their level of sexual function. While 
there were no significant differences between groups in 
the total FSFI score or domain scores for desire, arousal, 
lubrication, orgasm, satisfaction and pain at baseline or at 
6 and 12 weeks of treatment, LP demonstrated a trend 
towards an improvement in TC, urinary 8-isoprostane and 
significant within group improvement in IL-6 and IL-1β 
suggesting a role for LP in improving inflammation. 
Future research of the effectiveness of LP on women’s 
sexual well-being should focus on an older population of 
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